Commentary

Video

Choosing RNA Over DNA Testing for NRG1 Fusions in Pancreatic Cancer

Author(s):

E. Gabriela Chiorean, MD, SCCA

E. Gabriela Chiorean, MD, of Fred Hutch Cancer Center, discusses the benefits and challenges of DNA and RNA testing for NRG1 fusions in patients with pancreatic cancer.

Related Videos
Haley M. Hill, PA-C, discusses the role of multidisciplinary management in NRG1-positive non–small cell lung cancer and pancreatic cancer.
Haley M. Hill, PA-C, discusses preliminary data for zenocutuzumab in NRG1 fusion–positive non–small cell lung cancer and pancreatic cancer.
Haley M. Hill, PA-C, discusses how physician assistants aid in treatment planning for NRG1-positive non–small cell lung cancer and pancreatic cancer.
Haley M. Hill, PA-C, discusses DNA vs RNA sequencing for genetic testing in non–small cell lung cancer and pancreatic cancer.
Haley M. Hill, PA-C, discusses current approaches and treatment challenges in NRG1-positive non–small cell lung cancer and pancreatic cancer.
Tanios Bekaii-Saab, MD, FACP
Ryan Hood, BA, MD/MPH student, University of Miami Miller School of Medicine
Karyn A. Goodman, MD, MS
Kara N. Maxwell, MD, PhD
Tilak Sundaresan, MD
Related Content
Tanios S. Bekaii-Saab, MD
November 17th 2024

Molecular Testing Helps First-Line Treatment Landscape Evolve in Pancreatic Cancer

RMC-9805 was proven safe and active in patients with previously treated, KRAS G12D–mutant pancreatic ductal adenocarcinoma.
October 28th 2024

RMC-9805 Triggers Tumor Regressions in KRAS G12D–Mutant Pancreatic Cancer

US FDA
October 15th 2024

FDA Grants Orphan Drug Designation to IMM-1-104 for Pancreatic Cancer

Professor Casper van Eijck, pancreatic cancer surgeon, Erasmus MC
September 27th 2024

Dendritic Cell–Based Immunotherapy Data in Resected Pancreatic Cancer Published in JCO

Ilan Hadar, chairman, CEO, Silexion Therapeutics
September 24th 2024

LODER Plus SOC Chemotherapy Elicits Responses, Boosts OS in KRAS+ Unresectable, Locally Advanced Pancreatic Cancer

Narmafotinib Earns FDA Fast Track Designation for Advanced Pancreatic Cancer
September 20th 2024

Narmafotinib Earns FDA Fast Track Designation for Advanced Pancreatic Cancer